# A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat

Source: https://onco.cc/trials/nct06679985/  
OnCo record `nct06679985` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Toripalimab, Bevacizumab in hepatocellular carcinoma, run by Coherus Oncology, Inc., active and no longer recruiting.

## Summary

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT06679985 by Coherus Oncology, Inc., with 72 participants planned, started 2024-12-20 and due to reach its primary completion in 2027-09. Interventions recorded: Casdozokitug, Toripalimab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06679985
- Phase: 2
- Setting: A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
- Sponsor: Coherus Oncology, Inc.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT06679985: https://clinicaltrials.gov/study/NCT06679985

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)

---
JSON: https://onco.cc/api/v1/entities/nct06679985.json